Becton, Dickinson and Company $BDX Shares Purchased by Osaic Holdings Inc.

Osaic Holdings Inc. lifted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 23.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,703 shares of the medical instruments supplier’s stock after purchasing an additional 13,990 shares during the period. Osaic Holdings Inc.’s holdings in Becton, Dickinson and Company were worth $12,878,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Saudi Central Bank purchased a new stake in shares of Becton, Dickinson and Company in the first quarter valued at approximately $26,000. Bell Investment Advisors Inc increased its holdings in Becton, Dickinson and Company by 474.1% in the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 128 shares in the last quarter. Kelly Lawrence W & Associates Inc. CA acquired a new position in Becton, Dickinson and Company during the first quarter worth $31,000. Bank of Jackson Hole Trust lifted its holdings in Becton, Dickinson and Company by 85.6% during the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 95 shares in the last quarter. Finally, WPG Advisers LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $36,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 629 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $196.03, for a total value of $123,302.87. Following the transaction, the executive vice president directly owned 13,105 shares in the company, valued at approximately $2,568,973.15. This represents a 4.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bertram L. Scott sold 217 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the transaction, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,036 shares of company stock worth $197,225 over the last ninety days. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $195.72 on Friday. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $251.99. The stock has a market cap of $55.86 billion, a PE ratio of 33.57, a P/E/G ratio of 1.80 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The stock has a 50 day moving average price of $189.48 and a 200 day moving average price of $185.34.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The company had revenue of $5.32 billion during the quarter. Equities research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be given a dividend of $1.05 per share. The ex-dividend date is Monday, December 8th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 72.04%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on BDX shares. Royal Bank Of Canada upped their price target on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a research report on Wednesday. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Stifel Nicolaus lowered their price target on Becton, Dickinson and Company from $224.00 to $210.00 in a research note on Friday, November 7th. Morgan Stanley boosted their price target on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Finally, Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Four investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average target price of $205.64.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.